In the present study we demonstrated that RET51 isoform expression is higher in MTC cases harboring a RET somatic mutation with respect to cases with either a RAS somatic mutation (i.e., RAS+) or any somatic mutation (i.e., RET− and RAS−). This evidence concerns the gene RET and medullary thyroid gland carcinoma.